RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL CROSSOVER TRIAL IN ADULT ASTHMATICS EVALUATING THE EFFECT OF CONCOMITANT TWO WEEKS TREATMENT WITH MONTELUKAST (SINGULAIR) 10 MG ONCE DAILY OR MATCHING PLACEBO TO PREVENT THE DEVELOPMENT OF TOLERANCE TO BRONCHOPROTECTION AND BRONCHODILATION BY BETA-AGONISTS OCCURRING AFTER TWO WEEKS REGULAR TREATMENT WITH SALMETEROL (SEREVENT) 50microG B.I.D.
Latest Information Update: 31 May 2011
At a glance
- Drugs Montelukast (Primary) ; Salmeterol
- Indications Asthma
- Focus Therapeutic Use
- Acronyms PREDATOR
Most Recent Events
- 31 May 2011 New trial record